Semi-quantitative MRI Assessment of anti-PD1 Immunotherapy Response in Recurrent Glioblastoma
Lei Qin1,2, Xiang Li2,3, Amanda Stroiney4, David A Reardon1,2, and Geoffrey Young2,3
1Dana-Farber Cancer Institute, boston, MA, United States, 2Harvard Medical School, boston, MA, United States, 3Brigham and Women's Hospital, Boston, MA, United States, 4Northeastern University, Boston, MA, United States
The
purpose of this study is to evaluate the predictive value of quantitative and
semi-quantitative MRI biomarkers in determining patient benefit in anti-PD1
immunotherapy treatments. Longitudinal MRIs were performed on patients
diagnosed with recurrent GBM. Volumetric analysis of abnormal tissue from contrast
enhanced T1, FLAIR, and ADC revealed two distinct patterns: a) progressive
increase volume in patients who derived no significant benefit, and b) a
transient increase in the volume, followed by a delayed decrease in patients
with >6 mo survival on trial. In this preliminary study (n=10), the data
suggest that the volume of abnormal tissue on ADC seems to correlate better
with patient benefit than abnormality on FLAIR and T1.
This abstract and the presentation materials are available to members only;
a login is required.
